Why Prothena (PRTA) Hit an All-Time High Today

Update (4:10 p.m.): Updated with Wednesday market close information.

NEW YORK (TheStreet) -- Prothena  (PRTA) surged more than 25% and hit an all-time high of $47.48 on Wednesday, one day after the biotech company announced it would present clinical data at the XIV International Symposium on Amyloidosis in Indianapolis from April 27 to May 1.

In the wake of this news, RBC Capital Markets increased its target price on Prothena to $52 from $38 and maintained its "outperform" rating. The firm contends that the ISA abstract title indicates that the company's NEOD001 drug produced early cardiac responses in amyloidosis patients. The firm believes this outcome surpasses analysts' estimates and indicates the drug could be worth more than $500 million.

The stock closed at $47.39, up 27.53% or $10.23 from its previous close of $37.16. It amassed a volume of 1,858,633, well above its average of 243,923.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

PRTA Chart

PRTA data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

If you liked this article you might like

Cytokinetics Shares Plunge on Study Results for ALS Drug -- Biotech Movers

Cytokinetics Shares Plunge on Study Results for ALS Drug -- Biotech Movers

Zogenix Soars After Epilepsy Drug Meets Primary Endpoint -Biotech Movers

Zogenix Soars After Epilepsy Drug Meets Primary Endpoint -Biotech Movers

3 Stocks You Probably Never Heard Of Could Catch Fire Soon

3 Stocks You Probably Never Heard Of Could Catch Fire Soon

Prothena Raises $155.3M to Bring Anti-Organ Failure Drug to Market

Prothena Raises $155.3M to Bring Anti-Organ Failure Drug to Market